Story perspectives

Immunotherapy Trial Transforms Terminal Cancer Prognosis for Patient

3/15/2026

Summary

Story summary

Spencer Laird, a patient with microsatellite stable colorectal cancer, faced a two-year prognosis after cancer returned with 13 tumors.
His wife, CarleyAnn, sought alternative treatments.
This led him to enroll in a Duke University clinical trial testing immunotherapy as a first-line treatment.
The tumors shrank and the disease is no longer terminal.
Experts hope the trial will pave the way for immunotherapy as a standard treatment for similar cases.

1 of 1

Story summary

Spencer Laird, a patient with microsatellite stable colorectal cancer, faced a two-year prognosis after cancer returned with 13 tumors.
His wife, CarleyAnn, sought alternative treatments.
This led him to enroll in a Duke University clinical trial testing immunotherapy as a first-line treatment.
The tumors shrank and the disease is no longer terminal.
Experts hope the trial will pave the way for immunotherapy as a standard treatment for similar cases.